Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Tiziana Life Sciences LtdNASDAQ: TLSA
Net Debt · Q4 FY2025 · quarter ended Dec 2025
Net debt remains negative
Q4 FY2025 net debt was -$3.55M, compared with -$3.62M a year earlier.
Context
- Net debt amounted to 30.9% of total assets at the end of Q4 FY2025, down 1.1 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +1.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (3.55M) USD
- Year-over-year change
- +1.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.55M) | +1.8% |
| FY2024 | 2024-12-31 | (3.62M) | -286.5% |
| FY2023 | 2023-12-31 | (936K) | +94.7% |
| FY2022 | 2022-12-31 | (17.76M) | +56.5% |
| FY2021 | 2021-12-31 | (40.83M) | — |
Net Debt vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's Dec 2025 net debt of -$3.55M is the 4th highest of the 9 companies compared; the peer median is -$17.02M.
- Its year-over-year change of +1.8% is the 6th highest of 9, against a peer median of +78.5%.
- Net debt amounts to 30.9% of total assets for TLSA, versus a peer median of 20.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.72M | +2809.5% | -5.6% | 2.7% | |
| Mar 2026 | $6.59M | +120.8% | — | 3.3% | |
EXOZeXoZymes, Inc. | Mar 2026 | -$279.68K | +96.1% | — | 7.0% |
| Dec 2025 | -$3.55M | +1.8% | — | 30.9% | |
| Sep 2025 | -$4.03M | -309.4% | — | 86.9% | |
| Mar 2026 | -$30.01M | +72.2% | — | 13.8% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | -$34.79M | +84.7% | — | 27.3% |
| Mar 2026 | -$50.72M | -42.8% | — | 95.2% | |
| Mar 2026 | -$78.21M | -426.3% | — | 81.6% | |
| Peer median (excluding TLSA) | -$17.02M | +78.5% | -5.6% | 20.6% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 42.19M | 18.12M | 1.18M | 3.72M | 4.01M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.27M | 5.86M | 6.05M | 3.69M | 4.26M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 48.68M | 24.28M | 7.34M | 7.51M | 8.55M |
| Property, Plant & Equipment (Net) | 17K | 389K | 293K | 187K | 499K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 130K | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 1.81M | 4.55M | 3.59M | 2.44M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 147K | 2.2M | 4.85M | 3.78M | 2.94M |
| Total Assets | 48.83M | 26.48M | 12.18M | 11.28M | 11.5M |
| Account Payables | 4.41M | 4.96M | 4.14M | 5.58M | 7.17M |
| Short-term Debt | 1.36M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 530K |
| Other Current Liabilities | (1.35M) | 9K | 14K | 12K | (3K) |
| Total Current Liabilities | 7.55M | 6.66M | 6.54M | 7.35M | 11.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 243K | 109K | 0 | 234K |
| Total Liabilities | 7.55M | 6.91M | 6.65M | 7.35M | 11.44M |
| Common Stock | 102K | 102K | 103K | 111K | 121K |
| Retained Earnings | (108.06M) | (116.26M) | (133.68M) | (144.83M) | (44.41M) |
| Accumulated OCI | 119.15M | 115.57M | 117.06M | 116.99M | 9.68M |
| Other Stockholders Equity | 14.49M | 5.89M | 7.13M | 8.56M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.28M | 19.57M | 5.54M | 3.94M | 52K |
| Total Debt | 1.36M | 365K | 247K | 106K | 456K |
| Net Debt | (40.83M) | (17.76M) | (936K) | (3.62M) | (3.55M) |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.